Breast cancer index testing.

Ended Purchase Order Awarded Last action

Contract number
HT001424P0003
Awardee
Awarding agency
Obligated
$116,190

Award facts

Contract value 100% obligated
$116,190.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Not Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Bethesda, MD 20889, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00001 $116,190
Original award $0

About this award

Biotheranostics Inc. was awarded a $116,190 firm fixed price purchase order by the Defense Health Agency to provide breast cancer index testing services. As a self-certified small disadvantaged business, Biotheranostics will deliver genomic testing to guide cancer treatment decisions for military service members and veterans. The testing supports the agency's efforts to facilitate cancer screening, diagnosis, and care for its beneficiaries. No set aside was used for this procurement. Biotheranostics must complete the testing by October 10, 2023. As a division of Hologic, Inc., Biotheranostics leverages its parent company's expertise and resources to meet the Defense Health Agency's needs.

Quick answers

Who was awarded contract HT001424P0003?

HT001424P0003 was awarded to Biotheranostics Inc. by Defense Health Agency (Department of Defense) on October 1, 2023.

How much is contract HT001424P0003 worth?

The government has obligated $116,190 on HT001424P0003.

Was contract HT001424P0003 competed?

The extent of competition for HT001424P0003 was not competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award